See the DrugPatentWatch profile for nivolumab

Nivolumab is a type of immune checkpoint inhibitor used to treat various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It is administered intravenously and the recommended dose is 240 mg every two weeks or 480 mg every four weeks, according to the National Comprehensive Cancer Network (NCCN) guidelines [1].

Regarding the adjustment of nivolumab dosage based on a patient's weight, the drug's prescribing information does not provide specific dosage adjustments based on weight [2]. The U.S. Food and Drug Administration (FDA) has approved a fixed dosing regimen for nivolumab, regardless of a patient's weight [3].

It is worth noting that some studies have investigated the relationship between nivolumab exposure and patient outcomes, including weight as a potential factor. However, these studies have not resulted in changes to the recommended dosage regimen [4][5].

In summary, based on the available information, nivolumab dosage cannot be adjusted based on a patient's weight, as the FDA has approved a fixed dosing regimen. However, research is ongoing to understand the relationship between nivolumab exposure and patient outcomes.

Sources:
[1] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 2.2022. <https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf>
[2] Bristol Myers Squibb. Opdivo (nivolumab) Prescribing Information. <https://packageinserts.bms.com/pi/pi_opdivo.pdf>
[3] U.S. Food and Drug Administration. Highlights of Prescribing Information: OPDIVO (nivolumab) Injection, for intravenous use. <https://www.fda.gov/media/83319/download>
[4] Chau I, et al. Population pharmacokinetics of nivolumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2017;80(3):535-544. <https://doi.org/10.1007/s00280-017-3381-z>
[5] Yu H, et al. Population pharmacokinetics of nivolumab in patients with advanced cancer: a pooled analysis. Cancer Chemother Pharmacol. 2021;87(3):633-644. <https://doi.org/10.1007/s00280-021-04231-2>

(Note: DrugPatentWatch.com was not used as a source for this answer)